Edratide

Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE)[1][2][3].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Inflammation/Immunology

Edratide (20-50 µg; s.c.; once a week for 10 weeks) exerts beneficial effects on SLE is through regulation of gene expression[2]. Edratide (50 μg/mouse; s.c.; 10 weekly) reduces the rates of apoptosis and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL in SLE mouse[3]. Animal Model: 6-7 months female mice (with established SLE)[2] Dosage: 20-50 µg Administration: Subcutaneously injection; once a week for 10 weeks Result: Up-regulated the RNA transcripts of Tnfsf4, Il5ra, Zbtb20, Nid1, down-regulated the transcripts of Tfpi and S100a8. Animal Model: 7-8 months SLE-afflicted BWF1 female mice[3] Dosage: 50 μg/mouse Administration: S.c.; 10 weekly Result: Reduced apoptosis, down-regulated caspase-8 and caspase-3, and up-regulated Bcl-xL.